Provide a valuable resource to your clients or customers by linking to this resource page. Just place the following link on your website.
MariTide, also called maridebart cafraglutide or AMG 133, is an investigational antibody-peptide conjugate being developed by Amgen. It activates glucagon-like peptide-1 receptors and blocks glucose-dependent insulinotropic polypeptide receptors. As of October 2026, MariTide is not FDA-approved and is being evaluated in clinical trials for obesity, overweight, and related metabolic conditions.
read more about maritide ...MariTide combines activation of glucagon-like peptide-1 receptors with antagonism of glucose-dependent insulinotropic polypeptide receptors. These distinct actions affect signaling involved in appetite, food intake, and metabolic regulation. Its long-acting design is being studied for injections administered monthly or less frequently.
MariTide is being studied in adults with obesity or overweight, including patients with type 2 diabetes. Phase 3 programs also examine cardiovascular outcomes, heart failure, and obstructive sleep apnea in selected populations. These are research indications rather than approved medical uses.
MariTide is administered by subcutaneous injection in research studies. A published Phase 2 trial evaluated doses of 140 mg, 280 mg, and 420 mg every four weeks, along with selected eight-week dosing and dose-escalation schedules. Phase 3 trials are evaluating additional schedules. No FDA-approved dose or administration instructions exist, and participants receive treatment according to clinical trial protocols.
Gastrointestinal adverse events, including nausea and vomiting, were common in Phase 2 studies. Lower initial doses and gradual dose escalation reduced the frequency of these reactions. Longer-term safety, tolerability, and potential serious adverse events remain under evaluation in Phase 3 trials. MariTide has no FDA-approved prescribing information or established postmarketing safety profile.
No. MariTide remains an investigational medicine undergoing clinical trials as of October 2026.
Trials are evaluating obesity, overweight, type 2 diabetes, and selected obesity-related cardiovascular, heart failure, and sleep apnea outcomes.
Research has included injections every four or eight weeks, while ongoing studies are evaluating additional longer intervals.
Nausea, vomiting, and other gastrointestinal reactions were common in Phase 2 research. Longer-term safety is still being studied.
A GIPR Antagonist Conjugated to GLP-1 Analogues Promotes Weight Loss With Improved Metabolic Parameters in Preclinical and Phase 1 Settings. Nature Metabolism. https://www.nature.com/articles/s42255-023-00966-w. Date Accessed October 13, 2026.
Amgen Reports Second Quarter 2026 Financial Results. Amgen. https://www.amgen.com/newsroom/press-releases/2026/08/amgen-reports-second-quarter-2026-financial-results. Date Accessed October 13, 2026.
ClinicalTrials.gov - NCT05669599, Phase 2 Study of Maridebart Cafraglutide. U.S. National Library of Medicine. https://clinicaltrials.gov/study/NCT05669599. Date Accessed October 13, 2026.
Once-Monthly Maridebart Cafraglutide for the Treatment of Obesity - A Phase 2 Trial. New England Journal of Medicine. https://www.nejm.org/doi/10.1056/NEJMoa2504214. Date Accessed October 13, 2026.
Results From Amgen's Phase 2 Obesity Study of Monthly MariTide Presented at the American Diabetes Association 85th Scientific Sessions. Amgen. https://www.amgen.com/newsroom/press-releases/2025/06/results-from-amgens-phase-2-obesity-study-of-monthly-maritide-presented-at-the-american-diabetes-association-85th-scientific-sessions. Date Accessed October 13, 2026.